Regularity and mechanism of traditional Chinese medicine compound prescriptions in the treatment of primary osteoporosis

doi:10.12307/2024.326

Abstract

Abstract: BACKGROUND: Traditional Chinese medicine compound prescription has a long history in the treatment of primary osteoporosis, and the curative effect is definite, but the medication rule and mechanism are not clear.
OBJECTIVE: Using the methodology of data mining and network pharmacology, to explore and verify the law of drug use and molecular mechanism of modern traditional Chinese medicine in the treatment of primary osteoporosis.
METHODS: The relevant documents included in CNKI, WanFang, VIP and PubMed were used as data sources, and the relevant data were statistically counted and extracted by Microsoft EXCEL2019, IBMSPSS25.0 and other software. The high-frequency drugs obtained from the data statistics were analyzed by association rules analysis and cluster analysis, and the core drug combination of traditional Chinese medicine compound prescription in the treatment of primary osteoporosis was obtained by combining the two results. The therapeutic mechanism of this combination was explained by network pharmacology and verified by molecular docking.
RESULTS AND CONCLUSION: Finally, 151 articles were included and 207 prescriptions were selected, involving 285 flavors of Chinese herbs. (1) Ten groups of important drug combinations were obtained through the above two analyses, among which the core drug combination with the highest confidence and improvement was “Drynaria-Eucommia-Angelica.” The key components of the combination in the treatment of primary osteoporosis were quercetin, kaempferol, naringenin and so on. The core targets were SRC proto-oncogene, phosphoinositide-3-Kinase regulatory subunit 1 and RELA proto-oncogene. The main pathways were cancer signaling pathway, JAK-STAT signaling pathway, VEGF signaling pathway, and NF-κB signaling pathway. (2) The key active components were docked with the core targets, and the two showed a good combination. To conclude, Chinese herbal compound therapy in the treatment of primary osteoporosis can use a variety of active components to exert its efficacy through multiple signal pathways and acting on multiple targets, which can provide a theoretical basis for the research and development of new drugs for the follow-up treatment of primary osteoporosis.

Key words: primary osteoporosis, data mining, network pharmacology, Drynaria, Eucommia ulmoides, Angelica sinensis, molecular docking

CLC Number:

Zhang Jingtao, Hu Minhua, Liu Shitao, Li Shuyuan, Jiang Zexin, Zeng Wenxing, Ma Luyao, Zhou Qishi. Regularity and mechanism of traditional Chinese medicine compound prescriptions in the treatment of primary osteoporosis[J]. Chinese Journal of Tissue Engineering Research, 2024, 28(16): 2555-2560.

Figures/Tables 9

References

[1] 吴秀芳,秦飞,亓强,等.TEAS联合腰痛宁胶囊治疗原发性骨质疏松症疼痛的效果观察[J].川北医学院学报,2022,37(9):1157-1160.
[2] 揭威,黄小红,王燕玲,等.补肾益气化瘀汤治疗原发性骨质疏松症的临床疗效[J].临床合理用药杂志,2022,15(30):107-110.
[3] 董俊党,王其静,杨宁,等.唑来膦酸联合碳酸钙D3治疗骨质疏松骨痛的临床效果[J].临床合理用药杂志,2022,15(29):106-109.
[4] 宋敏,刘涛,巩彦龙,等.基于中医传承辅助平台系统的骨质疏松症组方用药规律分析[J].中国骨质疏松杂志,2017,23(4):519-523.
[5] 汤静,潘慧,徐松,等.抗骨质疏松药物不良反应回顾性分析[J].中国医院用药评价与分析,2008,8(12):950-951.
[6] 李焱,窦群立,杨锋.“肾为封藏之本”理论与原发性骨质疏松症发病机制的研究[J].中国骨质疏松杂志,2021,27(9):1369-1372.
[7] 翟子豪,谢义松.活血壮骨汤治疗肾虚血瘀型原发性骨质疏松症临床观察[J].山西中医,2022,38(4):33-35.
[8] 薛堃,邢秋娟,吴佶,等.益气化瘀补肾方联合抗阻运动治疗原发性骨质疏松症疗效研究[J].陕西中医,2022,43(3):321-324.
[9] 汤辰明,庞坚,石瑛.补肾中药改善原发性骨质疏松症慢性疼痛有效性的Meta分析[J].世界科学技术-中医药现代化,2021,23(8):2663-2671.
[10] 王佳辰,严红梅,周庆华,等.补益肝肾法治疗原发性骨质疏松症的临床研究[J].中国中医药现代远程教育,2018,16(14):50-51.
[11] 牛建明,杜志锋.中医药治疗骨质疏松症的研究进展[J].老年医学研究,2021, 2(2):53-56.
[12] 南京中医药大学.中药大辞典[M].上海:上海科学技术出版社,2006:14-3832.
[13] 国家中医药管理局.中华本草[M].上海:上海科学技术出版社,2005:200-700.
[14] 肖语雅,张华东,乌仁图雅,等.张华东教授治疗骨质疏松症临证经验[J].中国中医药现代远程教育,2020,18(20):67-69.
[15] 史恒蔚,李红专,马同,等.基于“正虚致痹”理论探讨“久病入络”与骨质疏松症的相关性机理[J].中国骨质疏松杂志,2020,26(9):1395-1398.
[16] 徐玉德,李盛华,周明旺,等.基于通络法探讨骨质疏松症与微循环障碍的相关性[J].中国骨质疏松杂志,2020,26(5):760-762.
[17] 包秀广.我院2019年中医药治疗骨质疏松症处方分析[J].临床医药文献电子杂志,2020,7(52):175+180.
[18] 强胜林,于海洋,蒋宜伟,等.基于“肝与大肠相通”理论谈肝-肠道微生态-骨质疏松症的相关性[J].中国骨质疏松杂志,2020,26(5):763-766.
[19] KENKRE JS, BASSETTJ. The bone remodelling cycle. Ann Clin Biochem. 2018;55(3): 308-327.
[20] SAAD FA. Novel insights into the complex architecture of osteoporosis molecular genetics. Ann N Y Acad Sci. 2020;1462(1):37-52.
[21] 李奕玉,关雅心,吴斌.双膦酸盐治疗原发性骨质疏松症的研究进展[J].实用医学杂志,2021,37(5):569-573.
[22] 刘彦芳,秦莉,张达,等.槲皮素的生物学活性研究进展[J].国际眼科杂志, 2009,9(5):941-943.
[23] SUN J, PAN Y, Li X, et al.Quercetin Attenuates Osteoporosis in Orchiectomy Mice by Regulating Glucose and Lipid Metabolism via the GPRC6A/AMPK/mTOR Signaling Pathway. Front Endocrinol (Lausanne). 2022;13:849544.
[24] VAKILI S, ZAL F, MOSTA FAVI-POUR Z, et al. Quercetin and vitamin E alleviate ovariectomy-induced osteoporosis by modulating autophagy and apoptosis in rat bone cells. J Cell Physiol. 2021;236(5):3495-3509.
[25] ABDULLAH A, RAVANAN P. Kaempferol mitigates Endoplasmic Reticulum Stress Induced Cell Death by targeting caspase 3/7. Sci Rep. 2018;8(1):2189.
[26] GAN L, LENG Y, MIN J , et al. Kaempferol promotes the osteogenesis in rBMSCs via mediation of SOX2/miR-124-3p/PI3K/Akt/mTOR axis. Eur J Pharmacol. 2022; 927:174954.
[27] 王雪峰,杨松,曹立新,等.山奈酚对卵巢去势大鼠的促骨胶原生成和减少骨小梁丢失的保护作用研究[J].中国临床药理学杂志,2020,36(10):1302-1305.
[28] SONG SH, WANG D, MO YY, et al. [Antiosteoporotic effects of naringenin on ovariectomy-induced osteoporosis in rat. Yao Xue Xue Bao. 2015;50(2): 154-161.
[29] GUO D, WANG J, WANG X, et al. Double directional adjusting estrogenic effect of naringin from Rhizoma drynariae (Gusuibu). J Ethnopharmacol. 2011;138(2):451-457.
[30] VIOLETTE SM, GUAN W, BARTLETT C, et al. Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption. Bone. 2001;28(1):54-64.
[31] ZHU H, CHEN H, DING D, et al. Overexpression of PIK3R1 Promotes Bone Formation by Regulating Osteoblast Differentiation and Osteoclast Formation. Comput Math Methods Med. 2021;2021:2909454.
[32] 倪佳,徐莹莹,邓婉玲,等.人MAPK3基因克隆及其在肝细胞癌细胞中的作用[J].遵义医科大学报,2022,45(4):463-469.
[33] XIAO P, CHEN Y, JIANG H, et al. In vivo genome-wide expression study on human circulating B cells suggests a novel ESR1 and MAPK3 network for postmenopausal osteoporosis. J Bone Miner Res. 2008;23(5):644-654.
[34] LI J. JAK-STAT and bone metabolism. JAKSTAT. 2013;2(3):e23930.
[35] GABER T, BRINKMAN ACK, PIENCZIKOWSKI J, et al. Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing. Int J Mol Sci. 2020;21(3):865.
[36] DAMERAU A , GABER T, OHMDORF S, et al. JAK/STAT Activation: A General Mechanism for Bone Development, Homeostasis, and Regeneration. Int J Mol Sci. 2020;21(23):9004.
[37] LIU XD, CAI F, LIU L, et al. MicroRNA-210 is involved in the regulation of postmenopausal osteoporosis through promotion of VEGF expression and osteoblast differentiation. Biol Chem. 2015;396(4):339-347.
[38] GRUNEWALD M, KUNAR S, SHARIFE S, et al. Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span. Science. 2021;373(6554):eabc8479.
[39] SONG N, ZHAO Z, MA X, et al. Naringin promotes fracture healing through stimulation of angiogenesis by regulating the VEGF/VEGFR-2 signaling pathway in osteoporotic rats. Chem Biol Interact. 2017;261:11-17.
[40] TIAN H , CHEN F, WANG Y, et al. Nur77 Prevents Osteoporosis by Inhibiting the NF-κB Signalling Pathway and Osteoclast Differentiation. J Cell Mol Med. 2022; 26(8):2163-2176.
[41] LUO H, GU R, OUYANG H, et al. Cadmium exposure induces osteoporosis through cellular senescence, associated with activation of NF-κB pathway and mitochondrial dysfunction. Environ Pollut. 2021;290:118043.